TB006 is an investigational drug. It has not been approved by the U.S. Food and Drug Administration (FDA), and its safety and effectiveness have not been established.
About TB006
TB006 is an investigational antibody currently being studied for Alzheimer’s disease. Researchers are evaluating how it works and whether it is safe and effective. Ongoing studies are assessing the potential impact of TB006 on Alzheimer’s symptoms and cognitive function.
About the Expanded Access Program
Expanded access is an FDA pathway that may allow some patients with serious conditions to receive an investigational drug outside of a clinical trial. TB006 is available at TIFAAR through an Expanded Access Program (EAP) authorized by the FDA.
Who may be eligible
Eligibility is determined by the program’s criteria and a physician’s evaluation. Not everyone who inquires will qualify. Because TB006 is an investigational drug, its safety and effectiveness have not yet been established.
What to expect
An initial conversation with our physician to review medical history and program criteria.
Informed consent, including a discussion of known and unknown risks.
Ongoing monitoring under the program’s protocol.
Learn more
Patients and families in The Woodlands and surrounding communities can contact our office with questions about the program: (346) 443-8165.
Frequently asked questions
Is TB006 FDA-approved?
No. TB006 is an investigational drug that has not been approved by the FDA. It is currently being studied.
Is TB006 effective for Alzheimer’s disease?
Its safety and effectiveness have not been established. TB006 remains under investigation.
What is an Expanded Access Program?
Expanded access is an FDA pathway that may allow some patients with serious conditions to receive an investigational drug outside of a clinical trial.
How is eligibility decided?
Eligibility depends on the program’s criteria and a physician’s evaluation. Not everyone who inquires will qualify.